Выходит 6 номеров в год
ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472
Indexed in
Gene Therapy in Type 1 Diabetes
Краткое описание
Type 1 diabetes (T1D) is caused by the autoimmune-mediated destruction of insulin-producing β cells in the pancreas. T1D affects as many as 3 million patients in the United States alone, with 15,000 new cases developing every year (Juvenile Diabetes Research Foundation), and presently there is no cure for T1D. In recent years, there has been a great deal of interest in developing gene therapy approaches to treat T1D. Gene therapy approaches tend to fall into three broad categoriesthose aimed at preventing or curing autoimmunity, those aimed at restoring insulin production through islet transplant or genetically engineered insulin production, and approaches that aim to prevent the morbidity and mortality associated with this complex disease. We review these studies here.
-
Sanlioglu Ahter D., Altunbas Hasan Ali, Balci Mustafa Kemal, Griffith Thomas S., Sanlioglu Salih, Insulin gene therapy from design to beta cell generation, Expert Reviews in Molecular Medicine, 14, 2012. Crossref
-
Baranyi Ulrike, Valenta Rudolf, Wekerle Thomas, Molecular chimerism in IgE-mediated allergy, Chimerism, 4, 1, 2013. Crossref
-
Li Shufa, Zhang Min, Xiang Fei, Zhao Jianyong, Jiang Chao, Zhu Jinkun, Dendritic cells expressing BTLA induces CD8+ T cell tolerance and attenuates the severity of diabetes, Vaccine, 29, 44, 2011. Crossref
-
Linden Rafael, Terapia gênica: o que é, o que não é e o que será, Estudos Avançados, 24, 70, 2010. Crossref
-
Yechoor Vijay, Chan Lawrence, Minireview: β-Cell Replacement Therapy for Diabetes in the 21st Century: Manipulation of Cell Fate by Directed Differentiation, Molecular Endocrinology, 24, 8, 2010. Crossref